Anti-pTpY Cdk1 [CP3.2]

Cyclin dependent kinase 1 (Cdk1) regulates cell cycle progression. It is active as a heterodimeric complex with cyclins. Cdk1 associates with cyclin A at the end of S phase and targets proteins such as p53, BARD1, and BRCA2 involved in cell cycle progression, and others involved in DNA replication. At the end of the G2 […]

Contributors

Inventor Institute
Julian Gannon Cancer Research UK, London Research Institute: Clare Hall Laboratories
Cat. #: 151684
Tool sub type: Primary antibody
Unit size: 100 ug
Research Fields: Cancer;Cell biology
Application: ELISA ; WB
Target: Cdk1
Reactivity: Mammalian ; Xenopus laevis
Clone: CP3.2
Host: Mouse
Class: Monoclonal
Alternate name: Cyclin-Dependent Kinase 1; Cell Division Cycle 2, G1 To S And G2 To M; Cell Division Protein Kinase 1; P34 Protein Kinase; P34CDC2; CDC28A; Cell Cycle Controller CDC2; CDKN1
Product description: Cyclin dependent kinase 1 (Cdk1) regulates cell cycle progression. It is active as a heterodimeric complex with cyclins. Cdk1 associates with cyclin A at the end of S phase and targets proteins such as p53, BARD1, and BRCA2 involved in cell cycle progression, and others involved in DNA replication. At the end of the G2 phase, Cdk1 associates with cyclin B1 and B2 to phosphorylate multiple protein targets required for transition from G2 to M phase, and progression through M phase. Cdk1 itself undergoes phosphorylation at Thr14 and Tyr15 by PKMYT1, which prevents nuclear translocation of Cdk1. Cdk1 is also phosphorylated at Tyr15 by WEE1/2 which inhibits both Cdk1 activity and transition from G2 to M phase. Conversely, dephosphorylation of Thr14 and Tyr15 by CDC25A/B activates Cdk1 and triggers mitosis. Cdk1 may also regulate epigenetic gene silencing through phosphorylation of EZH2 and maintenance of histone H3 lysine 27 trimethylation, which has been implicated in cancer
Conjugation: Unconjugated
Isotype: IgG1
Immunogen: Peptide – EKIGEGpTpYGVVYKGC – pT represents phosphorylated Thr14 and pY represents phosphorylated Tyr15
Myeloma used: Sp2/0-Ag14
Target background: Cyclin dependent kinase 1 (Cdk1) regulates cell cycle progression. It is active as a heterodimeric complex with cyclins. Cdk1 associates with cyclin A at the end of S phase and targets proteins such as p53, BARD1, and BRCA2 involved in cell cycle progression, and others involved in DNA replication. At the end of the G2 phase, Cdk1 associates with cyclin B1 and B2 to phosphorylate multiple protein targets required for transition from G2 to M phase, and progression through M phase. Cdk1 itself undergoes phosphorylation at Thr14 and Tyr15 by PKMYT1, which prevents nuclear translocation of Cdk1. Cdk1 is also phosphorylated at Tyr15 by WEE1/2 which inhibits both Cdk1 activity and transition from G2 to M phase. Conversely, dephosphorylation of Thr14 and Tyr15 by CDC25A/B activates Cdk1 and triggers mitosis. Cdk1 may also regulate epigenetic gene silencing through phosphorylation of EZH2 and maintenance of histone H3 lysine 27 trimethylation, which has been implicated in cancer
Format: Liquid
Concentration: 1 mg/ml
Storage buffer: PBS with 0.02% azide
Storage conditions: -15° C to -25° C
Shipping conditions: Dry ice
References:

Trickey et al. 2013. J Biol Chem. 288(2):928-37. PMID: 23195958.

Anaphase-promoting complex/cyclosome-mediated proteolysis of Ams2 in the G1 phase ensures the coupling of histone gene expression to DNA replication in fission yeast.

Related Tools for Antibodies

Cat. # Tool Name
151022 Anti-IL12 [1-1A4] Key Info View Tool
151023 Anti-IL12 [1-1D5] Key Info View Tool
151025 Anti-Vascular endothelium [10] Key Info View Tool
151034 Anti-HSVUL42 [13D11] Key Info View Tool
151040 Anti-CD11 & CD18 [24] Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.